OncoSil Medical (ASX:OSL) Beta: 3.1066 (As of Jul. 14, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

ASX:OSL OncoSil Medical Ltd ASX:OSL
48 GF Score
Price A$1.38
GF Value A$2.90
Valuation Possible Value Trap
! 4 Warning Signs
View Full Analysis

What is OncoSil Medical Beta?

OncoSil Medical ASX:OSL -1.79% 48 Beta is 3.1066 as of Jul. 14, 2026. GuruFocus rates ASX:OSL with a GF Score™ of 48/100 and a GF Value™ of A$2.90 (Possible Value Trap). The stock has 4 warning signs investors should review.

Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. As of today (2026-07-14), OncoSil Medical's Beta is 3.1066.


OncoSil Medical  (ASX:OSL) Beta Explanation

Beta is a measure of the volatility, or systematic risk, of a security or a portfolio in comparison to the market as a whole. We usually compare beta to 1. A beta of 1 indicates that the security's price will move with the market. A beta of less than 1 means that the security will be less volatile than the market. A beta of greater than 1 indicates that the security's price will be more volatile than the market.

Beta is primarily used in the Capital Asset Pricing Model (CAPM) to calculate the Cost of Equity, which can be used in the calculation of WACC %. The formula of Cost of Equity is:
Cost of Equity = Risk-Free Rate of Return + Beta of Asset * (Expected Return of the Market - Risk-Free Rate of Return)


OncoSil Medical Beta Related Terms


OncoSil Medical Beta Historical Data

* Premium members only.

The historical data trend for OncoSil Medical's Beta can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

OncoSil Medical Beta Chart

OncoSil Medical Annual Data
Trend Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23 Jun24 Jun25
Beta
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.33 0.68 1.83 1.51 3.39

OncoSil Medical Semi-Annual Data
Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Beta Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1.58 1.51 3.42 3.39 3.31

ASX:OSL vs ABT, SYK, MDT: Beta Comparison

For the Medical Devices subindustry, OncoSil Medical's Beta, along with its competitors' market caps and Beta data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


OncoSil Medical Beta vs Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, OncoSil Medical's Beta distribution charts can be found below:

* The bar in red indicates where OncoSil Medical's Beta falls into.


ASX:OSL
48GF Score
OncoSil Medical Ltd ASX:OSL
Beta is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

OncoSil Medical Beta Calculation

Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. A stock's beta can be calculated by dividing the product of the covariance of the individual stock's returns and the market's returns by the variance of the market's returns over a specified period. Basically, GuruFocus uses the returns calculated over three-year period.

Frequently Asked Questions Learn more about Beta →
What does a Beta of 3.1066 mean?
OncoSil Medical (ASX:OSL) has a Beta of 3.1066 as of Jul. 14, 2026. Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. View historical data for OncoSil Medical and its competitors.
Is OncoSil Medical's Beta too high?
OncoSil Medical's current Beta is 3.1066. Overall, OncoSil Medical has a GF Score™ of 48/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does OncoSil Medical's Beta compare to ABT and SYK?
OncoSil Medical's Beta of 3.1066 can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Beta for a Medical Devices & Instruments company?
A good Beta depends on the Medical Devices & Instruments industry context. However, Beta should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Beta mean?
A high Beta can signal that a stock is expensive relative to its fundamentals. Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. View historical data for OncoSil Medical and its competitors. OncoSil Medical's current Beta is 3.1066. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is OncoSil Medical stock overvalued right now?
Based on GuruFocus' analysis, OncoSil Medical (ASX:OSL) is currently considered Possible Value Trap. The stock's GF Value™ is A$2.90, compared to a current price of A$1.38 — trading 52.6% below its estimated fair value. The current Beta is 3.1066. OncoSil Medical's overall GF Score™ is 48/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Beta calculated?
Beta is calculated from a company's financial statements. For OncoSil Medical (ASX:OSL), the current Beta is 3.1066 as of Jul. 14, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is OncoSil Medical (ASX:OSL) Overvalued in 2026?

Based on GuruFocus' analysis, OncoSil Medical stock appears to be undervalued. The current stock price of A$1.38 is trading 52.6% below its estimated GF Value™ of A$2.90. GuruFocus considers OncoSil Medical to be Possible Value Trap.

Key valuation signals for ASX:OSL:

  • Beta: 3.1066
  • GF Value™: A$2.90 vs. price of A$1.38 (52.6% below fair value)
  • GF Score™: 48/100 with 4 warning signs

No single metric tells the full story. See the ASX:OSL stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


OncoSil Medical Business Description

Address 7 Eden Park Drive, Level 5, Macquarie Park, Sydney, NSW, AUS, 2113
OncoSil Medical Ltd is a medical device company. It is engaged in the development and commercialization of its product candidate, the OncoSil localized radiation therapy for the treatment of pancreatic and distal cholangiocarcinoma. It operates in one segment. the device development for new medical treatments. Geographically, the company derives its maximum revenue from Europe and the rest from Australia and New Zealand.
48GF Score

Get the complete analysis for ASX:OSL

Beta is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

A$1.38
Price
A$2.90
GF Value